DR. ATHANASIOS I. ZAVRAS, DDS, MS, DRMSC
Dentist at 168 St, New York, NY
License number
New York 50 - 055978
Category
Dentist
Type
Pediatric Dentistry
License number
New York DN1855922
Category
Dentist
Type
Pediatric Dentistry
License number
New York 50 - 055978
Category
Dentist
Type
Dental Public Health
License number
New York DN1855922
Category
Dentist
Type
Dental Public Health
Address
Address
2
622 W 168Th St SUITE PH17W-306, New York, NY 10032
64 Pine St, Dover, MA 02030
64 Pine St, Dover, MA 02030
Phone
(617) 818-0573
Personal information
See more information about ATHANASIOS I. ZAVRAS at radaris.comName
Address
Phone
64 Pine St, Dover, MA 02030
154 Langdon St, Newton, MA 02458
64 Pine St, Dover, MA 02030
188 Longwood Ave, Boston, MA 02115
Professional information
Dr. Athanasios I Zavras, New York NY - DDS (Doctor of Dental Surgery)
Specialties:
Pediatric Dentistry, Public Health Dentistry
Address:
622 W 168Th St SUITE PH17W-306, New York 10032
Languages:
English
Clinical Method For Individualized Epithelial Cancer Screening Involving Ercc5 And Igf2R Genetic Testing And Gene-Environment Interactions
US Patent:
2011026, Nov 3, 2011
Filed:
Apr 30, 2010
Appl. No.:
12/771197
Inventors:
Athanasios I. Zavras - Dover MA, US
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE - CAMBRIDGE MA
International Classification:
C12Q 1/68, A61B 5/00, G01N 33/566
US Classification:
435 614, 436501, 705 3
Abstract:
A system for determining individualized risk of developing aerodigestive cancers or cancers of the liver is described. Methods and compositions for assessing ERCC5 and/or IGF2R genetic variation and expression and their effects in view of certain environmental exposures in determining the risk of an individual for developing one or more epithelial cancers are provided. The system includes a kit used to collect a DNA sample from an individual and data related to the individual's medical and occupational history, use of tobacco and alcohol products as well as the individual's environment. An algorithm may be applied to transform the DNA sample and data into an individualized risk score, accounting for inter-individual variation in genetic profile and environmental/lifestyle exposures. The risk score may be indicative of the individual's risk of having or developing epithelial cancer, and the cancers prognosis. The risk score may be distributed to one or more of the individual, physician and other personnel. Test results and risk score have novel clinical utilities; diagnosis, prognosis, and treatment programs and activities may be facilitated by one or more of the kit and the risk score.
Genetic Risk Assessment Technology For Epithelial Cancer Involving Gene-Environment Interaction Between Ercc5 And Tobacco Use
US Patent:
2009025, Oct 8, 2009
Filed:
Jan 7, 2009
Appl. No.:
12/349785
Inventors:
Athanasios I. Zavras - Dover MA, US
Assignee:
President and Fellows of Harvard College - Cambridge MA
International Classification:
C12Q 1/68, C12N 15/12, C07K 14/435
US Classification:
435 6, 536 235, 435350
Abstract:
Methods and compositions for assessing ERCC5 gene expression in view of certain environmental exposures and determining the risk of an individual for developing one or more epithelial cancers are provided.
Genetic Risk Assessment Technology For Epithelial Cancer Involving Gene-Environment Interaction Between Ercc5 And Tobacco Use
US Patent:
2012005, Mar 8, 2012
Filed:
Nov 11, 2011
Appl. No.:
13/294360
Inventors:
Athanasios I. Zavras - Dover MA, US
Assignee:
President and Fellows of Harvard College - Cambridge MA
International Classification:
C12Q 1/68, C07K 14/435, C07H 21/04
US Classification:
435 612, 536 235, 530350, 435 614
Abstract:
Methods and compositions for assessing ERCC5 gene expression in view of certain environmental exposures and determining the risk of an individual for developing one or more epithelial cancers are provided.